ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
A Non-Randomized Study of the NightHawk Peripheral Plaque Excision System During Plaque Excision of Peripheral Arterial Disease

This study has been terminated.
( Other )

Sponsored by: FoxHollow Technologies
Information provided by: FoxHollow Technologies
ClinicalTrials.gov Identifier: NCT00516308
  Purpose

To assess the proximity of the catheter to the vessel wall and to correlate excised tissue with images collected by the integrated Optical coherence Tomography (OCT) imaging system. The primary endpoints are correlation between OCT images and histological characterization of excised tissue.


Condition Intervention Phase
Peripheral Vascular Diseases
Device: NightHawk
Phase II

MedlinePlus related topics:   Peripheral Vascular Diseases    Vascular Diseases   

U.S. FDA Resources

Study Type:   Interventional
Study Design:   Treatment, Non-Randomized, Open Label, Active Control, Single Group Assignment
Official Title:   A Non-Randomized Study of the NightHawk Peripheral Plaque Excision System During Plaque Excision of Peripheral Arterial Disease

Further study details as provided by FoxHollow Technologies:

Estimated Enrollment:   100
Study Start Date:   August 2007
Study Completion Date:   December 2007
Primary Completion Date:   December 2007 (Final data collection date for primary outcome measure)

  Eligibility
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Criteria

Inclusion Criteria:

  1. Patient requires treatment for peripheral arterial disease (PAD).
  2. Patient is willing and able to provide Informed Consent.
  3. Patient has at least one focal, de novo infrainguinal lesion in a native vessel.
  4. The minimum reference vessel diameter is 2.0 - 4.5 mm, dependent on the NightHawk device used.
  5. The lesion is ≥ 50% stenosed by quantitative vascular angiography.
  6. The lesion is ≤ 7 cm in length.
  7. The patient must be able to take at least one form of anti-platelet or anti-thrombotic therapy.

Exclusion Criteria:

  1. Patient presents with degree of limb disease or a co-existing medical condition that makes revascularization inappropriate.
  2. The patient has diffuse peripheral arterial disease and/or the disease is heavily calcified.
  3. Patient presents with concomitant disease contraindicating an endovascular intervention.
  4. Patient is pregnant.
  5. The patient has a hypersensitivity to contrast materials that cannot be adequately pretreated.
  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00516308

Locations
United States, Texas
Austin Heart    
      Austin, Texas, United States, 78756

Sponsors and Collaborators
FoxHollow Technologies
  More Information


Study ID Numbers:   FHT-P-07-004
First Received:   August 13, 2007
Last Updated:   January 16, 2008
ClinicalTrials.gov Identifier:   NCT00516308
Health Authority:   United States: Food and Drug Administration

Keywords provided by FoxHollow Technologies:
CLI  
Critical Limb Ischemia  
PAD  
Paripheral Arterial Disease  
Artherosclerosis  
Leg pain
Cardiovascular
Atherectomy
NightHawk

Study placed in the following topic categories:
Peripheral Vascular Diseases
Vascular Diseases
Pain
Ischemia

Additional relevant MeSH terms:
Cardiovascular Diseases

ClinicalTrials.gov processed this record on October 07, 2008




Links to all studies - primarily for crawlers